Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Decapeptyl, Pamorelin; Belgium: Decapeptyl, Salvacyl; Bulgaria: Decapeptyl, Diphereline; Cyprus: Arvekap; Czech Republic: Decapeptyl, Diphereline; Denmark: Decapeptyl, Pamorelin, Salvacyl; Estonia: Diphereline; Finland: Decapeptyl, Pamorelin, Salvacyl; France: Decapeptyl, Gonapeptyl, Salvacyl; Germany: Decapeptyl, Pamorelin, Salvacyl, Triptorelin, Uropeptyl; Greece: Arvekap, Gonapeptyl; Hungary: Decapeptyl, Diphereline, Gonapeptyl; Ireland: Decapeptyl, Gonapeptyl; Italy: Decapeptyl, Gonapeptyl; Latvia: Diphereline; Lithuania: Decapeptyl, Diphereline; Luxembourg: Decapeptyl; Malta: Arvekap, Gonapeptyl; Netherlands: Decapeptyl, Gonapeptyl, Pamorelin, Triptoreline, Salvacyl; Poland: Decapeptyl, Diphereline, Gonapeptyl; Portugal: Decapeptyl, Fertipeptil, Gonapeptyl; Romania: Diphereline, Gonapeptyl; Slovakia: Decapeptyl, Diphereline; Slovenia: Diphereline, Gonapeptyl; Spain: Decapeptyl; Sweden: Decapeptyl, Gonapeptyl, Moapar; UK: Decapeptyl, Gonapeptyl.

North America

Canada: Trelstar; USA: Trelstar.

Latin America

Argentina: Decapeptyl, Gonapeptyl; Brazil: Neo Decapeptyl; Mexico: Pamorelin.

Drug combinations


Triptorelin: C~64~H~82~N~18~O~13~. Mw: 1311.45. (1) Luteinizing hormone-releasing factor (pig), 6-D-tryptophan; (2) 5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-L-prolylglycinamide. CAS-57773-63-4 (1987).

Triptorelin Pamoate: C~23~H~16~O~6~. Mw: 1699.82. 5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-L-prolylglycine amide, 4,4′-methylenebis[3-hydroxy-2-naphthoate].CAS-124508-66-3 (2000).

Pharmacologic Category

Antineoplastic Agents; Endocrine Therapy; Gonadotropin Releasing Hormone Agonist. (ATC-Code: L02AE04).

Mechanism of action

Causes suppression of ovarian and testicular steroidogenesis due to decreased levels of LH and FSH with subsequent decrease in testosterone (male) and estrogen (female) levels.

Therapeutic use

Palliative treatment of advanced prostate cancer as alternative to orchiectomy or estrogen administration.

Pregnancy and lactiation implications

Contraindicated in women who are or may become pregnant. Excretion in breast milk unknown (contraindicated in nursing women).

Unlabeled use

Treatment of endometriosis, growth hormone deficiency, hyperandrogenism, in vitro fertilization, ovarian carcinoma, pancreatic carcinoma, precocious puberty, uterine leiomyomata.


Hypersensitivity to triptorelin or any component of the formulation, other LHRH agonists or LHRH. Pregnancy.

Warnings and precautions

Cases of spinal cord compression reported with LHRH agonists. Angioedema and anaphylaxis rarely occurred. Transient increases in testosterone can lead to worsening symptoms (bone pain, hematuria, bladder outlet obstruction) of prostate cancer during first few weeks of therapy. Rare cases of pituitary apoplexy (frequently secondary to pituitary adenoma) observed with leuprolide (may present as sudden headache, vomiting, visual or mental status changes, and infrequently cardiovascular collapse).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart